The healthcare giant just took a major step that could reshape its MedTech business and boost its dividend track record.

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Johnson & Johnson (JNJ) stock slips after the company's Q4 2025 earnings which beat on the topline but stood in line with the ...

Johnson & Johnson reports Q4 earnings Jan 21 with 22% EPS growth expected. Stelara biosimilars and talc verdict weigh on ...

Johnson & Johnson stock falls 1.7% despite beating Q4 earnings estimates with $2.46 EPS and strong 2026 guidance of $11.53 ...

The healthcare company’s forecast for 2026 tops Wall Street’s expectations.

By Diana Novak Jones Jan 20 (Reuters) - In a victory for thousands of women suing Johnson & Johnson over claims that the ...

Johnson & Johnson today reported fourth quarter results that beat The Street on sales but only matched on earnings.

Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” ...

J&J (JNJ) stock slips as a court-appointed special master allows plaintiffs of cancer claims linked to J&J's talc products to ...

A 75-year-old investor sits at a crossroads many retirees eventually reach: should he consolidate his holdings into something ...

It was a year that launched us into a new era of accelerated growth. Fueled by the strongest portfolio and pipeline in our ...